Hydra Biosciences is a privately held clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, that develops drugs to treat pain, inflammation, renal disease, anxiety and pulmonary disease using its expertise in novel ion channels. Hydra Biosciences’ proprietary platforms enable the company to identify and develop drug candidates that address significant unmet medical needs.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $10.5M
Founded date: 2001
Investors 2
| Date | Name | Website |
| 06.07.2021 | New Enterp... | nea.com |
| - | Accelerati... | accelerati... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 30.03.2015 | Series E | $10.5M | - |
Mentions in press and media 6
| Date | Title | Description |
| 03.01.2018 | Centrexion’s $67M Series D round to fund Phase 3 pain studies | Despite being just four years old, Centrexion is building a significant pipeline of non-opioid, non-steroidal pain medications. CNTX-4975 is being developed to treat pain from osteoarthritis and Morton’s Neuroma. The drug is a synthetic tra... |
| 10.02.2015 | Looks like BioVentures is in the midst of raising a new $100M fund | The venture firm typically invests $3 million to $10 million, it says, and does operate like your typical VC, however: “Generally, we like to see a business plan that calls for total capital requirement of $15 million to $20 million to reac... |
| 10.04.2011 | A key to birth control pills for men | By Nancy Fliesler It’s found only in the tails of sperm. It takes seven genes to build it. It gets activated as the sperm gets closer to the egg, giving it that extra whip and thrust to make it across the finish line. David Clapham, its dis... |
| 12.12.2008 | Biogen Idec VC Group Sees Opportunity in Tough Market, Has $100M New Allocation to Invest in Biotech Firms | Share Share on Facebook Share on Twitter LinkedIn Email Reprints It’s tough times for biotech entrepreneurs in search of new funds to launch startups, with early-stage investors conserving capital for their existing portfolio companies. Yet... |
| - | Centrexion’s $67M Series D round to fund Phase 3 pain studies | Boston-based Centrexion Therapeutics has finalized $67 million in Series D financing to fund upcoming phase 3 trials for its pain drug, CNTX-4975. Investors included New Enterprise Associates, which led the round, founding investor InterWes... |
| - | Looks like BioVentures is in the midst of raising a new $100M fund | Hey, life science startups: Looks like Massachusetts investment firm BioVentures is raising a new venture fund – and has raised about $20 million of a potential $100 million pot, according to a regulatory filing. Historically, the fund’s be... |